EcoDrugPlus

Solute Carrier Family 18 Member A2

Ensembl ID : ENSHBUG00000014615
Gene Symbol: SLC18A2
3 Cross references
216 Possible Orthologues:

Solute Carrier Family 22 Member 6-Like

Ensembl ID : ENSHBUG00000004138
Gene Symbol: LOC102292426
3 Cross references
358 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSHBUG00000015106
Gene Symbol: SLC29A1
3 Cross references
209 Possible Orthologues:

Solute Carrier Family 29 Member 1 (Augustine Blood Group)

Ensembl ID : ENSHBUG00000013779
Gene Symbol: SLC29A1
3 Cross references
209 Possible Orthologues:

Solute Carrier Family 5 Member 2

Ensembl ID : ENSHBUG00000001326
Gene Symbol: SLC5A2
3 Cross references
198 Possible Orthologues:

Solute Carrier Family 6 Member 1

Ensembl ID : ENSHBUG00000010057
Gene Symbol: SLC6A1
3 Cross references
208 Possible Orthologues:

Solute Carrier Family 6 Member 2

Ensembl ID : ENSHBUG00000023807
Gene Symbol: SLC6A2
3 Cross references
203 Possible Orthologues:

Solute Carrier Family 6 Member 3

Ensembl ID : ENSHBUG00000005189
Gene Symbol: SLC6A3
3 Cross references
166 Possible Orthologues:

Solute Carrier Family 6 Member 4

Ensembl ID : ENSHBUG00000003484
Gene Symbol: SLC6A4
3 Cross references
201 Possible Orthologues:

Solute Carrier Family 6 Member 9

Ensembl ID : ENSHBUG00000000086
Gene Symbol: SLC6A9
3 Cross references
208 Possible Orthologues:

Solute Carrier Family 9 Member A3

Ensembl ID : ENSHBUG00000017698
Gene Symbol: SLC9A3
3 Cross references
223 Possible Orthologues:

Solute Carrier Family 9 Member A3

Ensembl ID : ENSHBUG00000000512
Gene Symbol: SLC9A3
3 Cross references
222 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).